U.S. patent application number 12/350322 was filed with the patent office on 2009-04-30 for benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof.
This patent application is currently assigned to ASTRAZENECA AB. Invention is credited to Ziping Liu, Daniel Page, Christopher Walpole, Hua Yang.
Application Number | 20090111865 12/350322 |
Document ID | / |
Family ID | 29212435 |
Filed Date | 2009-04-30 |
United States Patent
Application |
20090111865 |
Kind Code |
A1 |
Liu; Ziping ; et
al. |
April 30, 2009 |
Benzimidazole Derivatives, Compositions Containing Them,
Preparation Thereof and Uses Thereof
Abstract
Compounds of formula I or pharmaceutically acceptable salts
thereof: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4
and Z are as defined in the specification as well as salts and
pharmaceutical compositions including the compounds are prepared.
They are useful in therapy, in particular in the management of
pain.
Inventors: |
Liu; Ziping; (Saint Laurent,
CA) ; Page; Daniel; (Saint Laurent, CA) ;
Walpole; Christopher; (Saint Laurent, CA) ; Yang;
Hua; (Saint Laurent, CA) |
Correspondence
Address: |
ASTRA ZENECA PHARMACEUTICALS LP;GLOBAL INTELLECTUAL PROPERTY
1800 CONCORD PIKE
WILMINGTON
DE
19850-5437
US
|
Assignee: |
ASTRAZENECA AB
Sodertalje
SE
|
Family ID: |
29212435 |
Appl. No.: |
12/350322 |
Filed: |
January 8, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10557806 |
Nov 22, 2005 |
7501447 |
|
|
PCT/GB04/02430 |
Jun 9, 2004 |
|
|
|
12350322 |
|
|
|
|
Current U.S.
Class: |
514/394 ;
548/304.4; 548/304.7 |
Current CPC
Class: |
C07D 235/08 20130101;
A61P 25/16 20180101; A61P 25/22 20180101; A61P 25/00 20180101; A61P
1/04 20180101; C07D 409/12 20130101; A61P 25/04 20180101; A61P 1/00
20180101; A61P 29/00 20180101; A61P 25/28 20180101; A61P 9/00
20180101 |
Class at
Publication: |
514/394 ;
548/304.7; 548/304.4 |
International
Class: |
A61K 31/4184 20060101
A61K031/4184; C07D 235/04 20060101 C07D235/04; A61P 25/00 20060101
A61P025/00 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 10, 2003 |
SE |
0301701-9 |
Claims
1. A compound of formula I or a pharmaceutically acceptable salt
thereof: ##STR00037## wherein Z is selected from O.dbd. and S.dbd.;
R.sup.1 is selected from C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, R.sup.5R.sup.6N--C.sub.1-6alkyl,
R.sup.5O--C.sub.1-6 alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2--C.sub.1-6alkyl,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, R.sup.5R.sup.6N--, R.sup.5O--,
R.sup.5C(.dbd.O)N(--R.sup.6)--, R.sup.5R.sup.6NS(.dbd.O).sub.2--,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl, C.sub.1-10
hydrocarbylamino, C.sub.6-10aryl, C.sub.6-10aryl-C(.dbd.O)--,
C.sub.3-10cycloalkyl, C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl
or C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6; R.sup.2 is selected from the group consisting of
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-10cycloalkyl, C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
R.sup.5R.sup.6N--, C.sub.3-5heteroaryl, C.sub.6-10aryl and
C.sub.3-6heterocycloalkyl, wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
C.sub.3-5heteroaryl, C.sub.6-10aryl or C.sub.3-6heterocycloalkyl
used in defining R.sup.2 is optionally substituted by one or more
groups selected from halogen, cyano, nitro, methoxy, ethoxy,
methyl, ethyl, hydroxy, and --NR.sup.5R.sup.6; wherein R.sup.5,
R.sup.6 and R.sup.7 are independently selected from --H,
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, and a divalent
C.sub.1-6group that together with another divalent R.sup.5, R.sup.6
or R.sup.7 forms a portion of a ring; and R.sup.3 is selected from
R.sup.8, R.sup.8O--, and R.sup.3R.sup.9N--; each of R.sup.4,
R.sup.8 and R.sup.9 is independently selected from --H,
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-10cycloalkyl, C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl, C.sub.6-10aryl,
C.sub.3-6heterocylcyl-C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl, and a divalent C.sub.1-6group that
together with another divalent group selected from R.sup.4, R.sup.8
and R.sup.9 forms a portion of a ring, wherein said
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-10cycloalkyl, C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl, C.sub.6-10aryl,
C.sub.3-6heterocylcyl-C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl, or divalent C.sub.1-6group is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and
amino.
2. A compound as claimed in claim 1, wherein Z is O.dbd.; R.sup.1
is selected from C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, R.sup.5R.sup.6N--C.sub.1-4alkyl,
R.sup.5O--C.sub.1-4alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-4alkyl,
phenyl-C.sub.1-4alkyl, phenyl-C(.dbd.O)--C.sub.1-4alkyl,
C.sub.3-10cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-4alkyl, R.sup.5R.sup.6N--,
R.sup.5O--, R.sup.5R.sup.6NS(.dbd.O).sub.2--, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-01cycloalkyl,
C.sub.4-6cycloalkenyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, phenyl-C.sub.1-4alkyl,
phenyl-C(.dbd.O)--C.sub.1-4alkyl,
C.sub.3-10cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-4alkyl, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-6cycloalkenyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6; wherein R.sup.5 and R.sup.6 are independently
selected from --H, C.sub.1-6alkyl and C.sub.2-6alkenyl; R.sup.2 is
selected from the group consisting of C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-4alkyl, C.sub.4-6cycloalkenyl,
C.sub.3-5heteroaryl, R.sup.5R.sup.6N--, phenyl and
C.sub.3-6heterocycloalkyl, wherein said C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-4alkyl, C.sub.4-6cycloalkenyl,
C.sub.3-5heteroaryl, phenyl or C.sub.3-6heterocycloalkyl used in
defining R.sup.2 is optionally substituted by one or more groups
selected from halogen, cyano, nitro, methoxy, ethoxy, methyl,
ethyl, hydroxy and amino; and R.sup.3 is selected from R.sup.8,
R.sup.8O--, R.sup.3HN-- and R.sup.8R.sup.9N--; R.sup.8 and R.sup.9
are independently selected from C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl, phenyl,
C.sub.3-6heterocylcyl-C.sub.1-4alkyl, and phenyl-C.sub.1-4alkyl,
wherein said C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-4alkyl, C.sub.3-6heterocyclyl, phenyl,
C.sub.3-6heterocylcyl-C.sub.1-4alkyl, or phenyl-C.sub.1-4alkyl is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;
and R.sup.4 is selected from --H, C.sub.1-6alkyl and
C.sub.2-6alkenyl.
3. A compound as claimed claim 1, wherein Z is O.dbd.; R.sup.1 is
selected from C.sub.1-6alkyl, C.sub.2-6alkenyl,
R.sup.5R.sup.6N--C.sub.1-4alkyl, R.sup.5O--C.sub.1-4alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-4alkyl,
phenyl-C.sub.1-4alkyl, phenyl-C(.dbd.O)--C.sub.1-4alkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-4alkyl, phenyl,
C.sub.3-6cycloalkyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-6alkyl,
C.sub.2-6alkenyl, R.sup.5R.sup.6N--C.sub.1-4alkyl,
R.sup.5O--C.sub.1-4alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-4alkyl,
phenyl-C.sub.1-4alkyl, phenyl-C(.dbd.O)--C.sub.1-4alkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-4alkyl, phenyl,
C.sub.3-6cycloalkyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6; R.sup.2 is selected from the group consisting of
C.sub.1-6alkyl, C.sub.3-6cycloalkyl, R.sup.5R.sup.6N--,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl, C.sub.3-5heteroaryl, and phenyl wherein
said C.sub.1-6alkyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl, C.sub.3-5heteroaryl, and phenyl used in
defining R.sup.2 is optionally substituted by one or more groups
selected from halogen, cyano, nitro, methoxy, ethoxy, methyl,
ethyl, hydroxy, and --NR.sup.5R.sup.6; R.sup.5 and R.sup.6 are
independently selected from --H, C.sub.1-6alkyl and
C.sub.2-6alkenyl; and R.sup.3 is selected from R.sup.8, R.sup.8O--,
R.sup.3HN-- and R.sup.3R.sup.9N--; R.sup.8 and R.sup.9 are
independently selected from C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.3-6cycloalkyl, C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.3-5heterocyclyl, phenyl,
C.sub.3-5heterocylcyl-C.sub.1-4alkyl, and phenyl-C.sub.1-4alkyl,
wherein said C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl, C.sub.3-5heterocyclyl, phenyl,
C.sub.3-5heterocylcyl-C.sub.1-4alkyl, or phenyl-C.sub.1-4alkyl is
optionally substituted by one or more groups selected from halogen,
cyano, methoxy, methyl, and ethyl; and R.sup.4 is selected from --H
and C.sub.1-4alkyl.
4. A compound as claimed in claim 1, wherein Z is O.dbd.; R.sup.1
is selected from cyclohexylmethyl, cyclopentylmethyl,
cyclobutylmethyl, cyclopropylmethyl, ethyl, propyl, adamantyl,
adamantylmethyl, allyl, isopentyl, benzyl, methoxyethyl,
tetrahydropyranylmethyl, tetrahydrofuranylmethyl, cyclohexyloxy,
cyclohexylamino, dimethylaminoethyl, 4-pyridylmethyl,
2-pyridylmethyl, 1-pyrrolylethyl, 1-morpholinoethyl,
4,4-difluorocyclohexylmethyl, cyclohexylmethyl, 2-pyrrolidylmethyl,
N-methyl-2-pyrrolidylmethyl, 2-piperidylmethyl,
N-methyl-2-piperidylmethyl, 3-thienylmethyl,
(2-nitrothiophene-5-yl)-methyl, (1-methyl-1H-imidazole-2-yl)methyl,
(5-(acetoxymethyl)-2-furyl)methyl),
(2,3-dihydro-1H-isoindole-1-yl)methyl, and 5-(2-methylthiazolyl);
R.sup.2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl,
cyclohexyl, cyclohexylmethyl, n-pentyl, isopentyl, trifluoromethyl,
1,1-difluoroethyl, N-piperidyl, dimethylamino, phenyl, pyridyl,
tetrahydrofuranyl, tetrahydropyranyl, 2-methoxy-2-propyl and
N-morpholinyl; R.sup.3 is selected from methyl, ethyl, isopropyl,
n-butyl, t-butyl, iso-butyl, phenyl, pyridyl, imidazolyl,
naphthalenyl, isopropylamino and 2-thienyl; and R.sup.4 is selected
from --H, methyl and ethyl.
5. A compound selected from:
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N-methylthioph-
ene-2-carboxamide,
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N,2,2-trimethy-
lpropanamide,
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N,2-dimethylpr-
opanamide,
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N,3--
dimethylbutanamide,
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N'-isopropyl-N-
-methylurea,
N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-yl]aceta-
mide,
N-[1-(Cyclohexylmethyl)-2-(1H-dimethylpropyl)-1H-benzimidazol-5-yl]--
N'-isopropylurea,
N-[1-(Cyclohexylmethyl)-2-(1H-dimethylpropyl)-1H-benzimidazol-5-yl]-2,2-d-
imethylbutanamide,
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]acetamide,
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N-methylacetam-
ide,
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-2,2-dimeth-
ylpropanamide, and pharmaceutically acceptable salts thereof.
6. A compound according to any one of claims 1-5 for use as a
medicament.
7. The use of a compound according to any one of claims 1-5 in the
manufacture of a medicament for the therapy of pain.
8. The use of a compound according to any one of claims 1-5 in the
manufacture of a medicament for the treatment of anxiety
disorders.
9. The use of a compound according to any one of claims 1-5 in the
manufacture of a medicament for the treatment of cancer, multiple
sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's
disease, gastrointestinal disorders and cardiavascular
disorders.
10. A pharmaceutical composition comprising a compound according to
any one of claims 1-5 and a pharmaceutically acceptable
carrier.
11. A method for the therapy of pain in a warm-blooded animal,
comprising the step of administering to said animal in need of such
therapy a therapeutically effective amount of a compound according
to any one of claims 1-5.
12. A method for preparing a compound of formula II, ##STR00038##
comprising the step of reacting a compound of formula III,
##STR00039## with a compound of R.sup.3C(.dbd.O)X to form the
compound of formula II, wherein X is selected from --Cl, --Br, --I,
--OH, --OCH.sub.3 and --OCH.sub.2CH.sub.3; R.sup.1 is selected from
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
R.sup.5R.sup.6N--C.sub.1-6alkyl, R.sup.5O--C.sub.1-6 alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2--C.sub.1-6alkyl,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, R.sup.5R.sup.6N--, R.sup.5O--,
R.sup.5C(.dbd.O)N(--R.sup.6)--, R.sup.5R.sup.6NS(.dbd.O).sub.2--,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and
--NR.sup.5R.sup.6; R.sup.2 is selected from the group consisting of
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
R.sup.5R.sup.6N--, C.sub.3-5heteroaryl, C.sub.6-10aryl and
C.sub.3-6heterocycloalkyl, wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
C.sub.3-5heteroaryl, C.sub.6-10aryl or C.sub.3-6heterocycloalkyl
used in defining R.sup.2 is optionally substituted by one or more
groups selected from halogen, cyano, nitro, methoxy, ethoxy,
methyl, ethyl, hydroxy and amino; wherein R.sup.5, R.sup.6 and
R.sup.7 are independently selected from --H, C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, and a divalent C.sub.1-6group
that together with another divalent R.sup.5, R.sup.6 or R.sup.7
forms a portion of a ring; R.sup.3 is selected from R.sup.8,
R.sup.8O--, R.sup.3NH--, R.sup.3R.sup.9N--; R.sup.8 and R.sup.9 are
independently selected from C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl, phenyl,
C.sub.3-6heterocylcyl-C.sub.1-4alkyl, and phenyl-C.sub.1-4alkyl,
wherein said C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-4alkyl, C.sub.3-6heterocyclyl, phenyl,
C.sub.3-6heterocylcyl-C.sub.1-4alkyl, or phenyl-C.sub.1-4alkyl is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;
and R.sup.4 is selected from --H, C.sub.1-6alkyl and
C.sub.2-6alkenyl.
13. A method for preparing a compound of formula IV, ##STR00040##
comprising the step of reacting a compound of formula V,
##STR00041## with a reducing agent selected from AlH.sub.3,
NaBH.sub.4, NaBH(O-iPr).sub.3, and LiAlH.sub.4, wherein R.sup.1 is
selected from C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, R.sup.5R.sup.6N--C.sub.1-6alkyl,
R.sup.5O--C.sub.1-6 alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2--C.sub.1-6alkyl,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, R.sup.5R.sup.6N--, R.sup.5O--,
R.sup.5C(.dbd.O)N(--R.sup.6)--, R.sup.5R.sup.6NS(.dbd.O).sub.2--,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and
R.sup.5R.sup.6N--; R.sup.2 is selected from the group consisting of
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
R.sup.5R.sup.6N--, C.sub.3-5heteroaryl, C.sub.6-10aryl and
C.sub.3-6heterocycloalkyl, wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
C.sub.3-5heteroaryl, C.sub.6-10aryl or C.sub.3-6heterocycloalkyl
used in defining R.sup.2 is optionally substituted by one or more
groups selected from halogen, cyano, nitro, methoxy, ethoxy,
methyl, ethyl, hydroxy and amino; wherein R.sup.5, R.sup.6 and
R.sup.7 are independently selected from --H, C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, and a divalent C.sub.1-6group
that together with another divalent R.sup.5, R.sup.6 or R.sup.7
forms a portion of a ring; and R.sup.10 is selected from --H,
C.sub.1-6alkyl, and C.sub.1-6alkenyl.
Description
[0001] This application is a divisional of application Ser. No.
10/557,806, filed Nov. 22, 2005, which is a US National Stage under
35 U.S.C .sctn. 371 of International Application No.
PCT/GB2004/002430, filed Jun. 9, 2004, which claims priority under
35 U.S.C. .sctn.119(a)-(d) to Swedish Application No. 0301701-9,
filed on Jun. 10, 2003.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The invention is related to therapeutic compounds which are
CB.sub.1 receptor ligands, pharmaceutical compositions containing
these compounds, manufacturing processes thereof and uses thereof,
and more particularly to compounds that are CB.sub.1 receptor
agonists. More particularly, the present invention is related to
compounds that may be effective in treating pain, cancer, multiple
sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's
disease, anxiety disorders, gastrointestinal disorders and
cardiavascular disorders.
[0004] 2. Discussion of Relevant Technology
[0005] Pain management has been an important field of study for
many years. It has been well known that cannabinoid receptor (e.g.,
CB.sub.1 receptor, CB.sub.2 receptor) ligands including agonists,
antagonists and inverse agonists produce relief of pain in a
variety of animal models by interacting with CB.sub.1 and/or
CB.sub.2 receptors. Generally, CB.sub.1 receptors are located
predominately in the central nervous system, whereas CB.sub.2
receptors are located primarily in the periphery and are primarily
restricted to the cells and tissues derived from the immune
system.
[0006] While CB.sub.1 receptor agonists, such as
.DELTA..sup.9-tetrahydrocannabinol (.DELTA..sup.9-THC) and
anadamide, are useful in anti-nociception models in animals, they
tend to exert undesired CNS side-effects, e.g., psychoactive side
effects, the abuse potential, drug dependence and tolerance, etc.
These undesired side effects are known to be mediated by the
CB.sub.1 receptors located in CNS. There are lines of evidence,
however, suggesting that CB1 agonists acting at peripheral sites or
with limited CNS exposure can manage pain in humans or animals with
much improved overall in vivo profile.
[0007] Therefore, there is a need for new CB.sub.1 receptor ligands
such as agonists, antagonists or inverse agonists that are useful
in managing pain or treating other related symptoms or diseases
with reduced or minimal undesirable CNS side-effects.
DISCLOSURE OF THE INVENTION
[0008] The present invention provides CB.sub.1 receptor ligands
which are useful in treating pain and other related symptoms or
diseases.
DEFINITIONS
[0009] Unless specified otherwise within this specification, the
nomenclature used in this specification generally follows the
examples and rules stated in Nomenclature of Organic Chemistry,
Sections A, B, C, D, E, F, and H, Pergamon Press, Oxford, 1979,
which is incorporated by references herein for its exemplary
chemical structure names and rules on naming chemical structures.
Optionally, a name of a compound may be generated using a chemical
naming program: ACD/ChemSketch, Version 5.09/September 2001,
Advanced Chemistry Development, Inc., Toronto, Canada.
[0010] "CB.sub.1/CB.sub.2 receptors" means CB.sub.1 and/or CB.sub.2
receptors.
[0011] The term "C.sub.m-n" or "C.sub.m-n group" used alone or as a
prefix, refers to any group having m to n carbon atoms, and having
0 to n multivalent heteroatoms selected from O, S, N and P, wherein
m and n are 0 or positive integers, and n>m. For example,
"C.sub.1-6" would refer to a chemical group having 1 to 6 carbon
atoms, and having 0 to 6 multivalent heteroatoms selected from O,
S, N and P.
[0012] The term "hydrocarbon" used alone or as a suffix or prefix,
refers to any structure comprising only carbon and hydrogen atoms
up to 14 carbon atoms. The term "hydrocarbon radical" or
"hydrocarbyl" used alone or as a suffix or prefix, refers to any
structure as a result of removing one or more hydrogens from a
hydrocarbon.
[0013] The term "alkyl" used alone or as a suffix or prefix, refers
to monovalent straight or branched chain hydrocarbon radicals
comprising 1 to about 12 carbon atoms. Unless otherwise specified,
"alkyl" general includes both saturated alkyl and unsaturated
alkyl.
[0014] The term "alkylene" used alone or as suffix or prefix,
refers to divalent straight or branched chain hydrocarbon radicals
comprising 1 to about 12 carbon atoms, which serves to links two
structures together.
[0015] The term "alkenyl" used alone or as suffix or prefix, refers
to a monovalent straight or branched chain hydrocarbon radical
having at least one carbon-carbon double bond and comprising at
least 2 up to about 12 carbon atoms.
[0016] The term "alkynyl" used alone or as suffix or prefix, refers
to a monovalent straight or branched chain hydrocarbon radical
having at least one carbon-carbon triple bond and comprising at
least 2 up to about 12 carbon atoms.
[0017] The term "cycloalkyl," used alone or as suffix or prefix,
refers to a monovalent ring-containing hydrocarbon radical
comprising at least 3 up to about 12 carbon atoms.
[0018] The term "cycloalkenyl" used alone or as suffix or prefix,
refers to a monovalent ring-containing hydrocarbon radical having
at least one carbon-carbon double bond and comprising at least 3 up
to about 12 carbon atoms.
[0019] The term "cycloalkynyl" used alone or as suffix or prefix,
refers to a monovalent ring-containing hydrocarbon radical having
at least one carbon-carbon triple bond and comprising about 7 up to
about 12 carbon atoms.
[0020] The term "aryl" used alone or as suffix or prefix, refers to
a monovalent hydrocarbon radical having one or more polyunsaturated
carbon rings having aromatic character, (e.g. 4n+2 delocalized
electrons) and comprising 5 up to about 14 carbon atoms, wherein
the radical is located on a carbon of the aromatic ring.
[0021] The term "non-aromatic group" or "non-aromatic" used alone,
as suffix or as prefix, refers to a chemical group or radical that
does not containing a ring having aromatic character (e.g., 4n+2
delocalized electrons).
[0022] The term "arylene" used alone or as suffix or prefix, refers
to a divalent hydrocarbon radical having one or more
polyunsaturated carbon rings having aromatic character, (e.g. 4n+2
delocalized electrons) and comprising 5 up to about 14 carbon
atoms, which serves to links two structures together.
[0023] The term "heterocycle" used alone or as a suffix or prefix,
refers to a ring-containing structure or molecule having one or
more multivalent heteroatoms, independently selected from N, O, P
and S, as a part of the ring structure and including at least 3 and
up to about 20 atoms in the ring(s). Heterocycle may be saturated
or unsaturated, containing one or more double bonds, and
heterocycle may contain more than one ring. When a heterocycle
contains more than one ring, the rings may be fused or unfused.
Fused rings generally refer to at least two rings share two atoms
therebetween. Heterocycle may have aromatic character or may not
have aromatic character.
[0024] The term "heteroalkyl" used alone or as a suffix or prefix,
refers to a radical formed as a result of replacing one or more
carbon atom of an alkyl with one or more heteroatoms selected from
N, O, P and S.
[0025] The term "heteroaromatic" used alone or as a suffix or
prefix, refers to a ring-containing structure or molecule having
one or more multivalent heteroatoms, independently selected from N,
O, P and S, as a part of the ring structure and including at least
3 and up to about 20 atoms in the ring(s), wherein the
ring-containing structure or molecule has an aromatic character
(e.g., 4n+2 delocalized electrons).
[0026] The term "heterocyclic group," "heterocyclic moiety,"
"heterocyclic," or "heterocyclo" used alone or as a suffix or
prefix, refers to a radical derived from a heterocycle by removing
one or more hydrogens therefrom.
[0027] The term "heterocyclyl" used alone or as a suffix or prefix,
refers a monovalent radical derived from a heterocycle by removing
one hydrogen from a carbon of a ring of the heterocycle.
[0028] The term "heterocyclylene" used alone or as a suffix or
prefix, refers to a divalent radical derived from a heterocycle by
removing two hydrogens therefrom, which serves to links two
structures together.
[0029] The term "heteroaryl" used alone or as a suffix or prefix,
refers to a heterocyclyl having aromatic character, wherein the
radical of the heterocyclyl is located on a carbon of an aromatic
ring of the heterocyclyl.
[0030] The term "heterocylcoalkyl" used alone or as a suffix or
prefix, refers to a heterocyclyl that does not have aromatic
character.
[0031] The term "heteroarylene" used alone or as a suffix or
prefix, refers to a heterocyclylene having aromatic character.
[0032] The term "heterocycloalkylene" used alone or as a suffix or
prefix, refers to a heterocyclylene that does not have aromatic
character.
[0033] The term "six-membered" used as prefix refers to a group
having a ring that contains six ring atoms.
[0034] The term "five-membered" used as prefix refers to a group
having a ring that contains five ring atoms.
[0035] A five-membered ring heteroaryl is a heteroaryl with a ring
having five ring atoms wherein 1, 2 or 3 ring atoms are
independently selected from N, O and S.
[0036] Exemplary five-membered ring heteroaryls are thienyl, furyl,
pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl,
isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl,
1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl,
1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and
1,3,4-oxadiazolyl.
[0037] A six-membered ring heteroaryl is a heteroaryl with a ring
having six ring atoms wherein 1, 2 or 3 ring atoms are
independently selected from N, O and S.
[0038] Exemplary six-membered ring heteroaryls are pyridyl,
pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
[0039] The term "substituted" used as a prefix refers to a
structure, molecule or group, wherein one or more hydrogens are
replaced with one or more C.sub.1-12hydrocarbon groups, or one or
more chemical groups containing one or more heteroatoms selected
from N, O, S, F, Cl, Br, I, and P. Exemplary chemical groups
containing one or more heteroatoms include heterocyclyl,
--NO.sub.2, --OR, --Cl, --Br, --I, --F, --CF.sub.3, --C(.dbd.O)R,
--C(.dbd.O)OH, --NH.sub.2, --SH, --NHR, --NR.sub.2, --SR,
--SO.sub.3H, --SO.sub.2R, --S(.dbd.O)R, --CN, --OH, --C(.dbd.O)OR,
--C(.dbd.O)NR.sub.2, --NRC(.dbd.O)R, oxo (.dbd.O), imino (.dbd.NR),
thio (.dbd.S), and oximino (.dbd.N--OR), wherein each "R" is a
C.sub.1-12hydrocarbyl. For example, substituted phenyl may refer to
nitrophenyl, pyridylphenyl, methoxyphenyl, chlorophenyl,
aminophenyl, etc., wherein the nitro, pyridyl, methoxy, chloro, and
amino groups may replace any suitable hydrogen on the phenyl
ring.
[0040] The term "substituted" used as a suffix of a first
structure, molecule or group, followed by one or more names of
chemical groups refers to a second structure, molecule or group,
which is a result of replacing one or more hydrogens of the first
structure, molecule or group with the one or more named chemical
groups. For example, a "phenyl substituted by nitro" refers to
nitrophenyl.
[0041] The term "optionally substituted" refers to both groups,
structures, or molecules that are substituted and those that are
not substituted.
[0042] Heterocycle includes, for example, monocyclic heterocycles
such as: aziridine, oxirane, thiirane, azetidine, oxetane,
thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine,
pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-dihydrofuran
tetrahydrofuran, thiophane, piperidine,
1,2,3,6-tetrahydro-pyridine, piperazine, morpholine,
thiomorpholine, pyran, thiopyran, 2,3-dihydropyran,
tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane,
dioxane, homopiperidine, 2,3,4,7-tetrahydro-1H-azepine
homopiperazine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin, and
hexamethylene oxide.
[0043] In addition, heterocycle includes aromatic heterocycles, for
example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene,
furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole,
isothiazole, isoxazole, 1,2,3-triazole, tetrazole,
1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole,
1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole,
1,3,4-thiadiazole, and 1,3,4-oxadiazole.
[0044] Additionally, heterocycle encompass polycyclic heterocycles,
for example, indole, indoline, isoindoline, quinoline,
tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline,
1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran,
2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman,
isochroman, xanthene, phenoxathiin, thianthrene, indolizine,
isoindole, indazole, purine, phthalazine, naphthyridine,
quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine,
perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine,
1,2-benzisoxazole, benzothiophene, benzoxazole, benzthiazole,
benzimidazole, benztriazole, thioxanthine, carbazole, carboline,
acridine, pyrolizidine, and quinolizidine.
[0045] In addition to the polycyclic heterocycles described above,
heterocycle includes polycyclic heterocycles wherein the ring
fusion between two or more rings includes more than one bond common
to both rings and more than two atoms common to both rings.
Examples of such bridged heterocycles include quinuclidine,
diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.
[0046] Heterocyclyl includes, for example, monocyclic
heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl,
azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl,
imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl,
2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl,
thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-pyridinyl, piperazinyl,
morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl,
2,3-dihydropyranyl, tetrahydropyranyl, 1,4-dihydropyridinyl,
1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl,
2,3,4,7-tetrahydro-1H-azepinyl, homopiperazinyl, 1,3-dioxepanyl,
4,7-dihydro-1,3-dioxepinyl, and hexamethylene oxidyl.
In addition, heterocyclyl includes aromatic heterocyclyls or
heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl,
thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl,
1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl,
1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl,
1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl.
[0047] Additionally, heterocyclyl encompasses polycyclic
heterocyclyls (including both aromatic or non-aromatic), for
example, indolyl, indolinyl, isoindolinyl, quinolinyl,
tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl,
1,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl,
2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl,
isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl,
isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl,
quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl,
phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl,
phenothiazinyl, phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl,
benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl,
thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl,
and quinolizidinyl.
[0048] In addition to the polycyclic heterocyclyls described above,
heterocyclyl includes polycyclic heterocyclyls wherein the ring
fusion between two or more rings includes more than one bond common
to both rings and more than two atoms common to both rings.
Examples of such bridged heterocycles include quinuclidinyl,
diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.
[0049] The term "alkoxy" used alone or as a suffix or prefix,
refers to radicals of the general formula --O--R, wherein --R is
selected from a hydrocarbon radical. Exemplary alkoxy includes
methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy,
cyclopropylmethoxy, allyloxy, and propargyloxy.
[0050] The term "aryloxy" used alone or as suffix or prefix, refers
to radicals of the general formula --O--Ar, wherein --Ar is an
aryl.
[0051] The term "heteroaryloxy" used alone or as suffix or prefix,
refers to radicals of the general formula --O--Ar', wherein --Ar'
is a heteroaryl.
[0052] The term "amine" or "amino" used alone or as a suffix or
prefix, refers to radicals of the general formula --NRR', wherein R
and R' are independently selected from hydrogen or a hydrocarbon
radical.
[0053] "Acyl" used alone, as a prefix or suffix, means
--C(.dbd.O)--R, wherein --R is an optionally substituted
hydrocarbyl, hydrogen, amino or alkoxy. Acyl groups include, for
example, acetyl, propionyl, benzoyl, phenyl acetyl, carboethoxy,
and dimethylcarbamoyl.
[0054] Halogen includes fluorine, chlorine, bromine and iodine.
[0055] "Halogenated," used as a prefix of a group, means one or
more hydrogens on the group is replaced with one or more
halogens.
[0056] "RT" or "rt" means room temperature.
[0057] A first ring group being "fused" with a second ring group
means the first ring and the second ring share at least two atoms
therebetween.
[0058] "Link," "linked," or "linking," unless otherwise specified,
means covalently linked or bonded.
[0059] When a first group, structure, or atom is "directly
connected" to a second group, structure or atom, at least one atom
of the first group, structure or atom forms a chemical bond with at
least one atom of the second group, structure or atom.
[0060] "Saturated carbon" means a carbon atom in a structure,
molecule or group wherein all the bonds connected to this carbon
atom are single bond. In other words, there is no double or triple
bonds connected to this carbon atom and this carbon atom generally
adopts an sp.sup.3 atomic orbital hybridization.
[0061] "Unsaturated carbon" means a carbon atom in a structure,
molecule or group wherein at least one bond connected to this
carbon atom is not a single bond. In other words, there is at least
one double or triple bond connected to this carbon atom and this
carbon atom generally adopts a sp or sp.sup.2 atomic orbital
hybridization.
[0062] In the context of the present specification, the term
"therapy" also includes "prophylaxis" unless there are specific
indications to the contrary. The term "therapeutic" and
"therapeutically" should be construed accordingly. The term
"therapy" within the context of the present invention further
encompasses to administer an effective amount of a compound of the
present invention, to mitigate either a pre-existing disease state,
acute or chronic, or a recurring condition. This definition also
encompasses prophylactic therapies for prevention of recurring
conditions and continued therapy for chronic disorders.
SUMMARY OF THE INVENTION
[0063] This invention encompasses compounds in accord with formula
I:
##STR00002##
wherein
[0064] Z is selected from O.dbd. and S.dbd.;
[0065] R.sup.1 is selected from C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, R.sup.5R.sup.6N--C.sub.1-6alkyl,
R.sup.5O--C.sub.1-6 alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2--C.sub.1-6alkyl,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, R.sup.5R.sup.6N--, R.sup.5O--,
R.sup.5C(.dbd.O)N(--R.sup.6)--, R.sup.5R.sup.6NS(.dbd.O).sub.2--,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6;
[0066] R.sup.2 is selected from the group consisting of
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-10cycloalkyl, C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
R.sup.5R.sup.6N--, C.sub.3-5heteroaryl, C.sub.6-10aryl and
C.sub.3-6heterocycloalkyl, wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
C.sub.3-5heteroaryl, C.sub.6-10aryl or C.sub.3-6heterocycloalkyl
used in defining R.sup.2 is optionally substituted by one or more
groups selected from halogen, cyano, nitro, methoxy, ethoxy,
methyl, ethyl, hydroxy, and --NR.sup.5R.sup.6;
[0067] wherein R.sup.5, R.sup.6 and R.sup.7 are independently
selected from --H, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, and a divalent C.sub.1-6group that together with
another divalent R.sup.5, R.sup.6 or R.sup.7 forms a portion of a
ring; and
[0068] R.sup.3 is selected from R.sup.5, R.sup.8O--, and
R.sup.8R.sup.9N--;
[0069] each of R.sup.4, R.sup.8 and R.sup.9 is independently
selected from --H, C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, C.sub.3-10cycloalkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl, C.sub.3-6heterocyclyl,
C.sub.6-10aryl, C.sub.3-6heterocylcyl-C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl, and a divalent C.sub.1-6group that
together with another divalent group selected from R.sup.4, R.sup.8
and R.sup.9 forms a portion of a ring, wherein said
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-10cycloalkyl, C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl, C.sub.6-10aryl,
C.sub.3-6heterocylcyl-C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl, or divalent C.sub.1-6group is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6.
[0070] The invention also encompasses stereoisomers, enantiomers,
diastereomers, racemates or mixtures thereof, in-vivo-hydrolysable
precursors and pharmaceutically-acceptable salts of compounds of
formula I, solvated or unsolvated forms of compounds of formula I,
pharmaceutical compositions and formulations containing them,
methods of using them to treat diseases and conditions either alone
or in combination with other therapeutically-active compounds or
substances, processes and intermediates used to prepare them, uses
of them as medicaments, uses of them in the manufacture of
medicaments and uses of them for diagnostic and analytic
purposes.
DESCRIPTION OF PREFERRED EMBODIMENTS
[0071] In one aspect, the invention provides a compound of formula
I, a pharmaceutically acceptable salt thereof, diastereomers,
enantiomers, or mixtures thereof:
##STR00003##
wherein
[0072] Z is selected from O.dbd. and S.dbd.;
[0073] R.sup.1 is selected from C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, R.sup.5R.sup.6N--C.sub.1-6alkyl,
R.sup.5O--C.sub.1-6 alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2--C.sub.1-6alkyl,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, R.sup.5R.sup.6N--, R.sup.5O--,
R.sup.5C(.dbd.O)N(--R.sup.6)--, R.sup.5R.sup.6NS(.dbd.O).sub.2--,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6;
[0074] R.sup.2 is selected from the group consisting of
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-10cycloalkyl, C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
R.sup.5R.sup.6N--, C.sub.3-5heteroaryl, C.sub.6-10aryl and
C.sub.3-6heterocycloalkyl, wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
C.sub.3-5heteroaryl, C.sub.6-10aryl or C.sub.3-6heterocycloalkyl
used in defining R.sup.2 is optionally substituted by one or more
groups selected from halogen, cyano, nitro, methoxy, ethoxy,
methyl, ethyl, hydroxy, and --NR.sup.5R.sup.6;
[0075] wherein R.sup.5, R.sup.6 and R.sup.7 are independently
selected from --H, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, and a divalent C.sub.1-6group that together with
another divalent R.sup.5, R.sup.6 or R.sup.7 forms a portion of a
ring; and
[0076] R.sup.3 is selected from R.sup.8, R.sup.8O--, and
R.sup.3R.sup.9N--;
[0077] each of R.sup.4, R.sup.8 and R.sup.9 is independently
selected from --H, C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, C.sub.3-10cycloalkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl, C.sub.3-6heterocyclyl,
C.sub.6-10aryl, C.sub.3-6heterocylcyl-C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl, and a divalent C.sub.1-6group that
together with another divalent group selected from R.sup.4, R.sup.8
and R.sup.9 forms a portion of a ring, wherein said
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-10cycloalkyl, C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl, C.sub.6-10aryl,
C.sub.3-6heterocylcyl-C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl, or divalent C.sub.1-6group is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6.
[0078] Particularly, the compounds of the present invention are
those of formula I, wherein
[0079] Z is O.dbd.;
[0080] R.sup.1 is selected from C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, R.sup.5R.sup.6N--C.sub.1-4alkyl,
R.sup.5O--C.sub.1-4alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-4aryl, phenyl-C.sub.1-4alkyl,
phenyl-C(.dbd.O)--C.sub.1-4alkyl,
C.sub.3-10cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-4alkyl, R.sup.5R.sup.6N--,
R.sup.5O--, R.sup.5R.sup.6NS(.dbd.O).sub.2--, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-6cycloalkenyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, phenyl-C.sub.1-4alkyl,
phenyl-C(.dbd.O)--C.sub.1-4alkyl,
C.sub.3-10cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-4alkyl, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-6cycloalkenyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6;
[0081] wherein R.sup.5 and R.sup.6 are independently selected from
--H, C.sub.1-6alkyl and C.sub.2-6alkenyl;
[0082] R.sup.2 is selected from the group consisting of
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-4alkyl, C.sub.4-6cycloalkenyl,
C.sub.3-5heteroaryl, R.sup.5R.sup.6N--, phenyl and
C.sub.3-6heterocycloalkyl, wherein said C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-4alkyl, C.sub.4-6cycloalkenyl,
C.sub.3-5heteroaryl, phenyl or C.sub.3-6heterocycloalkyl used in
defining R.sup.2 is optionally substituted by one or more groups
selected from halogen, cyano, nitro, methoxy, ethoxy, methyl,
ethyl, hydroxy and amino; and
[0083] R.sup.3 is selected from R.sup.8, R.sup.8O--, R.sup.8HN--
and R.sup.8R.sup.9N--;
[0084] R.sup.8 and R.sup.9 are independently selected from
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-4alkyl, C.sub.3-6heterocyclyl, phenyl,
C.sub.3-6heterocylcyl-C.sub.1-4alkyl, and phenyl-C.sub.1-4alkyl,
wherein said C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-4alkyl, C.sub.3-6heterocyclyl, phenyl,
C.sub.3-6heterocylcyl-C.sub.1-4alkyl, or phenyl-C.sub.1-4alkyl is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;
and
[0085] R.sup.4 is selected from --H, C.sub.1-6alkyl and
C.sub.2-6alkenyl.
[0086] More particularly, the compounds of the present invention
are those of formula I,
[0087] wherein Z is O.dbd.;
[0088] R.sup.1 is selected from C.sub.1-6alkyl, C.sub.2-6alkenyl,
R.sup.5R.sup.6N--C.sub.1-4alkyl, R.sup.5O--C.sub.1-4alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-4alkyl,
phenyl-C.sub.1-4alkyl, phenyl-C(.dbd.O)--C.sub.1-4alkyl,
C.sub.3-10cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-4alkyl, phenyl,
C.sub.3-10cycloalkyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-6alkyl,
C.sub.2-6alkenyl, R.sup.5R.sup.6N--C.sub.1-4alkyl,
R.sup.5O--C.sub.1-4alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-4alkyl,
phenyl-C.sub.1-4alkyl, phenyl-C(.dbd.O)--C.sub.1-4alkyl,
C.sub.3-10cycloalkyl-C.sub.1-4alkyl,
C.sub.4-6cycloalkenyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C.sub.1-4alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-4alkyl, phenyl,
C.sub.3-10cycloalkyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6;
[0089] R.sup.2 is selected from the group consisting of
C.sub.1-6alkyl, C.sub.3-6cycloalkyl, R.sup.5R.sup.6N--,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl, C.sub.3-5heteroaryl, and phenyl wherein
said C.sub.1-6alkyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-4alkyl,
C.sub.3-6heterocycloalkyl, C.sub.3-5heteroaryl, and phenyl used in
defining R.sup.2 is optionally substituted by one or more groups
selected from halogen, cyano, nitro, methoxy, ethoxy, methyl,
ethyl, hydroxy and amino;
[0090] R.sup.5 and R.sup.6 are independently selected from --H,
C.sub.1-6alkyl and C.sub.2-6alkenyl; and
[0091] R.sup.3 is selected from R.sup.8, R.sup.8O--, R.sup.8HN--
and R.sup.8R.sup.9N--;
[0092] R.sup.8 and R.sup.9 are independently selected from
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl, C.sub.3-5heterocyclyl, phenyl,
C.sub.3-5heterocylcyl-C.sub.1-4alkyl, and phenyl-C.sub.1-4alkyl,
wherein said C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-4alkyl, C.sub.3-5heterocyclyl, phenyl,
C.sub.3-5heterocylcyl-C.sub.1-4alkyl, or phenyl-C.sub.1-4alkyl is
optionally substituted by one or more groups selected from halogen,
cyano, methoxy, methyl, and ethyl; and
[0093] R.sup.4 is selected from --H and C.sub.1-4alkyl.
[0094] Most particularly, the compounds of the present invention
are those of formula I, wherein
[0095] Z is O.dbd.;
[0096] R.sup.1 is selected from cyclohexylmethyl,
cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, ethyl,
propyl, adamantyl, adamantylmethyl, allyl, isopentyl, benzyl,
methoxyethyl, tetrahydropyranylmethyl, tetrahydrofuranylmethyl,
cyclohexyloxy, cyclohexylamino, dimethylaminoethyl,
4-pyridylmethyl, 2-pyridylmethyl, 1-pyrrolylethyl,
1-morpholinoethyl, 4,4-difluorocyclohexylmethyl, cyclohexylmethyl,
2-pyrrolidylmethyl, N-methyl-2-pyrrolidylmethyl, 2-piperidylmethyl,
N-methyl-2-piperidylmethyl, 3-thienylmethyl,
(2-nitrothiophene-5-yl)-methyl, (1-methyl-1H-imidazole-2-yl)methyl,
(5-(acetoxymethyl)-2-furyl)methyl),
(2,3-dihydro-1H-isoindole-1-yl)methyl, and
5-(2-methylthiazolyl);
[0097] R.sup.2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl,
cyclohexyl, cyclohexylmethyl, n-pentyl, isopentyl, trifluoromethyl,
1,1-difluoroethyl, N-piperidyl, dimethylamino, phenyl, pyridyl,
tetrahydrofuranyl, tetrahydropyranyl, 2-methoxy-2-propyl and
N-morpholinyl;
[0098] R.sup.3 is selected from methyl, ethyl, isopropyl, n-butyl,
t-butyl, iso-butyl, phenyl, pyridyl, imidazolyl, naphthalenyl,
isopropylamino and 2-thienyl; and
[0099] R.sup.4 is selected from --H, methyl and ethyl.
[0100] It will be understood that when compounds of the present
invention contain one or more chiral centers, the compounds of the
invention may exist in, and be isolated as, enantiomeric or
diastereomeric forms, or as a racemic mixture. The present
invention includes any possible enantiomers, diastereomers,
racemates or mixtures thereof, of a compound of Formula I. The
optically active forms of the compound of the invention may be
prepared, for example, by chiral chromatographic separation of a
racemate, by synthesis from optically active starting materials or
by asymmetric synthesis based on the procedures described
thereafter.
[0101] It will also be appreciated that certain compounds of the
present invention may exist as geometrical isomers, for example E
and Z isomers of alkenes. The present invention includes any
geometrical isomer of a compound of Formula I. It will further be
understood that the present invention encompasses tautomers of the
compounds of the formula I.
[0102] It will also be understood that certain compounds of the
present invention may exist in solvated, for example hydrated, as
well as unsolvated forms. It will further be understood that the
present invention encompasses all such solvated forms of the
compounds of the formula I.
[0103] Within the scope of the invention are also salts of the
compounds of the formula I. Generally, pharmaceutically acceptable
salts of compounds of the present invention may be obtained using
standard procedures well known in the art, for example by reacting
a sufficiently basic compound, for example an alkyl amine with a
suitable acid, for example, HCl or acetic acid, to afford a
physiologically acceptable anion. It may also be possible to make a
corresponding alkali metal (such as sodium, potassium, or lithium)
or an alkaline earth metal (such as a calcium) salt by treating a
compound of the present invention having a suitably acidic proton,
such as a carboxylic acid or a phenol with one equivalent of an
alkali metal or alkaline earth metal hydroxide or alkoxide (such as
the ethoxide or methoxide), or a suitably basic organic amine (such
as choline or meglumine) in an aqueous medium, followed by
conventional purification techniques.
[0104] In one embodiment, the compound of formula I above may be
converted to a pharmaceutically acceptable salt or solvate thereof,
particularly, an acid addition salt such as a hydrochloride,
hydrobromide, phosphate, acetate, fumarate, maleate, tartrate,
citrate, methanesulphonate or p-toluenesulphonate.
[0105] We have now found that the compounds of the invention have
activity as pharmaceuticals, in particular as modulators or ligands
such as agonists, partial agonists, inverse agonist or antagonists
of CB1 receptors. More particularly, the compounds of the invention
exhibit selective activity as agonist of the CB1 receptors and are
useful in therapy, especially for relief of various pain conditions
such as chronic pain, neuropathic pain, acute pain, cancer pain,
pain caused by rheumatoid arthritis, migraine, visceral pain etc.
This list should however not be interpreted as exhaustive.
Additionally, compounds of the present invention are useful in
other disease states in which dysfunction of CB1 receptors is
present or implicated. Furthermore, the compounds of the invention
may be used to treat cancer, multiple sclerosis, Parkinson's
disease, Huntington's chorea, Alzheimer's disease, anxiety
disorders, gastrointestinal disorders and cardiovascular
disorders.
[0106] Compounds of the invention are useful as immunomodulators,
especially for autoimmune diseases, such as arthritis, for skin
grafts, organ transplants and similar surgical needs, for collagen
diseases, various allergies, for use as anti-tumour agents and anti
viral agents.
[0107] Compounds of the invention are useful in disease states
where degeneration or dysfunction of cannabinoid receptors is
present or implicated in that paradigm. This may involve the use of
isotopically labelled versions of the compounds of the invention in
diagnostic techniques and imaging applications such as positron
emission tomography (PET).
[0108] Compounds of the invention are useful for the treatment of
diarrhoea, depression, anxiety and stress-related disorders such as
post-traumatic stress disorders, panic disorder, generalized
anxiety disorder, social phobia, and obsessive compulsive disorder,
urinary incontinence, premature ejaculation, various mental
illnesses, cough, lung oedema, various gastro-intestinal disorders,
e.g. constipation, functional gastrointestinal disorders such as
Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's
disease and other motor disorders, traumatic brain injury, stroke,
cardioprotection following myocardial infarction, spinal injury and
drug addiction, including the treatment of alcohol, nicotine,
opioid and other drug abuse and for disorders of the sympathetic
nervous system for example hypertension.
[0109] Compounds of the invention are useful as an analgesic agent
for use during general anaesthesia and monitored anaesthesia care.
Combinations of agents with different properties are often used to
achieve a balance of effects needed to maintain the anaesthetic
state (e.g. amnesia, analgesia, muscle relaxation and sedation).
Included in this combination are inhaled anaesthetics, hypnotics,
anxiolytics, neuromuscular blockers and opioids.
[0110] Also within the scope of the invention is the use of any of
the compounds according to the formula I above, for the manufacture
of a medicament for the treatment of any of the conditions
discussed above.
[0111] A further aspect of the invention is a method for the
treatment of a subject suffering from any of the conditions
discussed above, whereby an effective amount of a compound
according to the formula I above, is administered to a patient in
need of such treatment.
[0112] Thus, the invention provides a compound of formula I, or
pharmaceutically acceptable salt or solvate thereof, as
hereinbefore defined for use in therapy.
[0113] In a further aspect, the present invention provides the use
of a compound of formula I, or a pharmaceutically acceptable salt
or solvate thereof, as hereinbefore defined in the manufacture of a
medicament for use in therapy.
[0114] The compounds of the present invention are useful in
therapy, especially for the therapy of various pain conditions
including, but not limited to: acute pain, chronic pain,
neuropathic pain, back pain, cancer pain, and visceral pain.
[0115] In use for therapy in a warm-blooded animal such as a human,
the compound of the invention may be administered in the form of a
conventional pharmaceutical composition by any route including
orally, intramuscularly, subcutaneously, topically, intranasally,
intraperitoneally, intrathoracially, intravenously, epidurally,
intrathecally, intracerebroventricularly and by injection into the
joints.
[0116] In one embodiment of the invention, the route of
administration may be orally, intravenously or intramuscularly.
[0117] The dosage will depend on the route of administration, the
severity of the disease, age and weight of the patient and other
factors normally considered by the attending physician, when
determining the individual regimen and dosage level at the most
appropriate for a particular patient.
[0118] For preparing pharmaceutical compositions from the compounds
of this invention, inert, pharmaceutically acceptable carriers can
be either solid and liquid. Solid form preparations include
powders, tablets, dispersible granules, capsules, cachets, and
suppositories.
[0119] A solid carrier can be one or more substances, which may
also act as diluents, flavoring agents, solubilizers, lubricants,
suspending agents, binders, or table disintegrating agents; it can
also be an encapsulating material.
[0120] In powders, the carrier is a finely divided solid, which is
in a mixture with the finely divided compound of the invention, or
the active component. In tablets, the active component is mixed
with the carrier having the necessary binding properties in
suitable proportions and compacted in the shape and size
desired.
[0121] For preparing suppository compositions, a low-melting wax
such as a mixture of fatty acid glycerides and cocoa butter is
first melted and the active ingredient is dispersed therein by, for
example, stirring. The molten homogeneous mixture in then poured
into convenient sized moulds and allowed to cool and solidify.
[0122] Suitable carriers are magnesium carbonate, magnesium
stearate, talc, lactose, sugar, pectin, dextrin, starch,
tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a
low-melting wax, cocoa butter, and the like.
[0123] The term composition is also intended to include the
formulation of the active component with encapsulating material as
a carrier providing a capsule in which the active component (with
or without other carriers) is surrounded by a carrier which is thus
in association with it. Similarly, cachets are included.
[0124] Tablets, powders, cachets, and capsules can be used as solid
dosage forms suitable for oral administration.
[0125] Liquid form compositions include solutions, suspensions, and
emulsions. For example, sterile water or water propylene glycol
solutions of the active compounds may be liquid preparations
suitable for parenteral administration. Liquid compositions can
also be formulated in solution in aqueous polyethylene glycol
solution.
[0126] Aqueous solutions for oral administration can be prepared by
dissolving the active component in water and adding suitable
colorants, flavoring agents, stabilizers, and thickening agents as
desired. Aqueous suspensions for oral use can be made by dispersing
the finely divided active component in water together with a
viscous material such as natural synthetic gums, resins, methyl
cellulose, sodium carboxymethyl cellulose, and other suspending
agents known to the pharmaceutical formulation art.
[0127] Depending on the mode of administration, the pharmaceutical
composition will preferably include from 0.05% to 99% w (percent by
weight), more preferably from 0.10 to 50% w, of the compound of the
invention, all percentages by weight being based on total
composition.
[0128] A therapeutically effective amount for the practice of the
present invention may be determined, by the use of known criteria
including the age, weight and response of the individual patient,
and interpreted within the context of the disease which is being
treated or which is being prevented, by one of ordinary skills in
the art.
[0129] Within the scope of the invention is the use of any compound
of formula I as defined above for the manufacture of a
medicament.
[0130] Also within the scope of the invention is the use of any
compound of formula I for the manufacture of a medicament for the
therapy of pain.
[0131] Additionally provided is the use of any compound according
to Formula I for the manufacture of a medicament for the therapy of
various pain conditions including, but not limited to: acute pain,
chronic pain, neuropathic pain, back pain, cancer pain, and
visceral pain.
[0132] A further aspect of the invention is a method for therapy of
a subject suffering from any of the conditions discussed above,
whereby an effective amount of a compound according to the formula
I above, is administered to a patient in need of such therapy.
[0133] Additionally, there is provided a pharmaceutical composition
comprising a compound of Formula I, or a pharmaceutically
acceptable salt thereof, in association with a pharmaceutically
acceptable carrier.
[0134] Particularly, there is provided a pharmaceutical composition
comprising a compound of Formula I, or a pharmaceutically
acceptable salt thereof, in association with a pharmaceutically
acceptable carrier for therapy, more particularly for therapy of
pain.
[0135] Further, there is provided a pharmaceutical composition
comprising a compound of Formula I, or a pharmaceutically
acceptable salt thereof, in association with a pharmaceutically
acceptable carrier use in any of the conditions discussed
above.
[0136] In a further aspect, the present invention provides a method
of preparing the compounds of the present invention.
[0137] In one embodiment, the invention provides a process for
preparing a compound of formula II,
##STR00004##
comprising the step of reacting a compound of formula III,
##STR00005##
with a compound of R.sup.3C(.dbd.O)X to form the compound of
formula II, wherein
[0138] X is selected from --Cl, --Br, --I, --OH, --OCH.sub.3 and
--OCH.sub.2CH.sub.3;
[0139] R.sup.1 is selected from C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, R.sup.5R.sup.6N--C.sub.1-6alkyl,
R.sup.5O--C.sub.1-6 alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2--C.sub.1-6alkyl,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, R.sup.5R.sup.6N--, R.sup.5O--,
R.sup.5C(.dbd.O)N(--R.sup.6)--, R.sup.5R.sup.6NS(.dbd.O).sub.2--,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and
--NR.sup.5R.sup.6;
[0140] R.sup.2 is selected from the group consisting of
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
R.sup.5R.sup.6N--, C.sub.3-5heteroaryl, C.sub.6-10aryl and
C.sub.3-6heterocycloalkyl, wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
C.sub.3-5heteroaryl, C.sub.6-10aryl or C.sub.3-6heterocycloalkyl
used in defining R.sup.2 is optionally substituted by one or more
groups selected from halogen, cyano, nitro, methoxy, ethoxy,
methyl, ethyl, hydroxy and amino;
[0141] wherein R.sup.5, R.sup.6 and R.sup.7 are independently
selected from --H, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, and a divalent C.sub.1-6group that together with
another divalent R.sup.5, R.sup.6 or R.sup.7 forms a portion of a
ring;
[0142] R.sup.3 is selected from R.sup.8, R.sup.8O--, R.sup.3NH--,
and R.sup.3R.sup.9N--;
[0143] R.sup.8 and R.sup.9 are independently selected from
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-4alkyl, C.sub.3-6heterocyclyl, phenyl,
C.sub.3-6heterocylcyl-C.sub.1-4alkyl, and phenyl-C.sub.1-4alkyl,
wherein said C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-4alkyl, C.sub.3-6heterocyclyl, phenyl,
C.sub.3-6heterocylcyl-C.sub.1-4alkyl, or phenyl-C.sub.1-4alkyl is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;
and
[0144] R.sup.4 is selected from --H, C.sub.1-6alkyl and
C.sub.2-6alkenyl.
[0145] Particularly, the present invention provides a method of
preparing a compound of formula II, wherein Z is O.dbd.;
[0146] R.sup.1 is selected from cyclohexylmethyl,
cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, ethyl,
propyl, adamantyl, adamantylmethyl, allyl, isopentyl, benzyl,
methoxyethyl, tetrahydropyranylmethyl, tetrahydrofuranylmethyl,
cyclohexyloxy, cyclohexylamino, dimethylaminoethyl,
4-pyridylmethyl, 2-pyridylmethyl, 1-pyrrolylethyl,
1-morpholinoethyl, 4,4-difluorocyclohexylmethyl, cyclohexylmethyl,
2-pyrrolidylmethyl, N-methyl-2-pyrrolidylmethyl, 2-piperidylmethyl,
N-methyl-2-piperidylmethyl, 3-thienylmethyl,
(2-nitrothiophene-5-yl)-methyl, (1-methyl-1H-imidazole-2-yl)methyl,
(5-(acetoxymethyl)-2-furyl)methyl),
(2,3-dihydro-1H-isoindole-1-yl)methyl, and
5-(2-methylthiazolyl);
[0147] R.sup.2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl,
cyclohexyl, cyclohexylmethyl, n-pentyl, isopentyl, trifluoromethyl,
1,1-difluoroethyl, N-piperidyl, dimethylamino, phenyl, pyridyl,
tetrahydrofuranyl, tetrahydropyranyl, 2-methoxy-2-propyl and
N-morpholinyl;
[0148] R.sup.3 is selected from methyl, ethyl, isopropyl, n-butyl,
t-butyl, iso-butyl, phenyl, pyridyl, imidazolyl, naphthalenyl,
isopropylamino and 2-thienyl; and
[0149] R.sup.4 is selected from --H, methyl and ethyl.
[0150] In a further aspect, the present invention provides a method
for preparing a compound of formula IV,
##STR00006##
comprising the step of reacting a compound of formula V,
##STR00007##
with a reducing agent selected from AlH.sub.3, NaBH.sub.4,
NaBH(O-iPr).sub.3, and LiAlH.sub.4, wherein
[0151] R.sup.1 is selected from C.sub.1-10alkyl, C.sub.2-10alkenyl,
C.sub.2-10alkynyl, R.sup.5R.sup.6N--C.sub.1-6alkyl,
R.sup.5O--C.sub.1-6 alkyl,
R.sup.5C(.dbd.O)N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2--C.sub.1-6alkyl,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--C.sub.1-6alkyl,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--C.sub.1-6alkyl,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--C.sub.1-6alkyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, R.sup.5R.sup.6N--, R.sup.5O--,
R.sup.5C(.dbd.O)N(--R.sup.6)--, R.sup.5R.sup.6NS(.dbd.O).sub.2--,
R.sup.5CS(.dbd.O).sub.2N(--R.sup.6)--,
R.sup.5R.sup.6NC(.dbd.O)N(--R.sup.7)--,
R.sup.5R.sup.6NS(.dbd.O).sub.2N(R.sup.7)--, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl and
C.sub.3-6heterocyclyl-C(.dbd.O)--; wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.6-10aryl-C.sub.1-6alkyl,
C.sub.6-10aryl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.3-10cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C.sub.1-6alkyl,
C.sub.3-6heterocyclyl-C(.dbd.O)--C.sub.1-6alkyl,
C.sub.1-10hydrocarbylamino, C.sub.6-10aryl,
C.sub.6-10aryl-C(.dbd.O)--, C.sub.3-10cycloalkyl,
C.sub.4-8cycloalkenyl, C.sub.3-6heterocyclyl or
C.sub.3-6heterocyclyl-C(.dbd.O)-- used in defining R.sup.1 is
optionally substituted by one or more groups selected from halogen,
cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and
amino;
[0152] R.sup.2 is selected from the group consisting of
C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
R.sup.5R.sup.6N--, C.sub.3-5heteroaryl, C.sub.6-10aryl and
C.sub.3-6heterocycloalkyl, wherein said C.sub.1-10alkyl,
C.sub.2-10alkenyl, C.sub.2-10alkynyl, C.sub.3-8cycloalkyl,
C.sub.3-8cycloalkyl-C.sub.1-6alkyl,
C.sub.4-8cycloalkenyl-C.sub.1-6alkyl,
C.sub.3-6heterocycloalkyl-C.sub.1-6alkyl, C.sub.4-8cycloalkenyl,
C.sub.3-5heteroaryl, C.sub.6-10aryl or C.sub.3-6heterocycloalkyl
used in defining R.sup.2 is optionally substituted by one or more
groups selected from halogen, cyano, nitro, methoxy, ethoxy,
methyl, ethyl, hydroxy, and --NR.sup.5R.sup.6;
[0153] wherein R.sup.5, R.sup.6 and R.sup.7 are independently
selected from --H, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, and a divalent C.sub.1-6group that together with
another divalent R.sup.5, R.sup.6 or R.sup.7 forms a portion of a
ring; and
[0154] R.sup.10 is selected from --H, C.sub.1-6alkyl, and
C.sub.1-6alkenyl.
[0155] Particularly, the present invention provides a method of
preparing a compound of formula IV, wherein
[0156] R.sup.1 is selected from cyclohexylmethyl,
cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, ethyl,
propyl, adamantyl, adamantylmethyl, allyl, isopentyl, benzyl,
methoxyethyl, tetrahydropyranylmethyl, tetrahydrofuranylmethyl,
cyclohexyloxy, cyclohexylamino, dimethylaminoethyl,
4-pyridylmethyl, 2-pyridylmethyl, 1-pyrrolylethyl,
1-morpholinoethyl, 4,4-difluorocyclohexylmethyl, cyclohexylmethyl,
2-pyrrolidylmethyl, N-methyl-2-pyrrolidylmethyl, 2-piperidylmethyl,
N-methyl-2-piperidylmethyl, 3-thienylmethyl,
(2-nitrothiophene-5-yl)-methyl, (1-methyl-1H-imidazole-2-yl)methyl,
(5-(acetoxymethyl)-2-furyl)methyl),
(2,3-dihydro-1H-isoindole-1-yl)methyl, and
5-(2-methylthiazolyl);
[0157] R.sup.2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl,
cyclohexyl, cyclohexylmethyl, n-pentyl, isopentyl, trifluoromethyl,
1,1-difluoroethyl, N-piperidyl, dimethylamino, phenyl, pyridyl,
tetrahydrofuranyl, tetrahydropyranyl, 2-methoxy-2-propyl and
N-morpholinyl; and
[0158] R.sup.10 is selected from --H and C.sub.1-6alkyl.
[0159] Compounds of the present invention may be prepared according
to the synthetic routes as depicted in Schemes 1 and 2 using one or
more methods disclosed above.
##STR00008##
##STR00009##
Biological Evaluation
[0160] hCB.sub.1 and hCB.sub.2 Receptor Binding
[0161] Human CB.sub.1 receptor from Receptor Biology (hCB1) or
human CB.sub.2 receptor from BioSignal (hCB2) membranes are thawed
at 37.degree. C., passed 3 times through a 25-gauge blunt-end
needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5
mM EDTA, 5 mM MgCl.sub.2, and 0.5 mg/mL BSA fatty acid free, pH
7.4) and aliquots containing the appropriate amount of protein are
distributed in 96-well plates. The IC.sub.50 of the compounds of
the invention at hCB.sub.1 and hCB.sub.2 are evaluated from
10-point dose-response curves done with .sup.3H--CP55,940 at 20000
to 25000 dpm per well (0.17-0.21 nM) in a final volume of 300 PI.
The total and non-specific binding are determined in the absence
and presence of 0.2 .mu.M of HU210 respectively. The plates are
vortexed and incubated for 60 minutes at room temperature, filtered
through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with
the Tomtec or Packard harvester using 3 mL of wash buffer (50 mM
Tris, 5 mM MgCl.sub.2, 0.5 mg BSA pH 7.0). The filters are dried
for 1 hour at 55.degree. C. The radioactivity (cpm) is counted in a
TopCount (Packard) after adding 65 .mu.l/well of MS-20
scintillation liquid.
hCB.sub.1 and hCB.sub.2 GTP.gamma.S binding
[0162] Human CB.sub.1 receptor from Receptor Biology (hCB1) or
human CB.sub.2 receptor membranes (BioSignal) are thawed at
37.degree. C., passed 3 times through a 25-gauge blunt-end needle
and diluted in the GTP.gamma.S binding buffer (50 mM Hepes, 20 mM
NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl.sub.2, pH 7.4, 0.1% BSA).
The EC.sub.50 and E.sub.max of the compounds of the invention are
evaluated from 10-point dose-response curves done in 30011 with the
appropriate amount of membrane protein and 100000-130000 dpm of
GTPg.sup.35S per well (0.11-0.14 nM). The basal and maximal
stimulated binding is determined in absence and presence of 1 .mu.M
(hCB.sub.2) or 10 .mu.M (hCB.sub.1) Win 55, 212-2 respectively. The
membranes are pre-incubated for 5 minutes with 56.25 .mu.M (hCB2)
or 112.5 .mu.M (hCB.sub.1) GDP prior to distribution in plates (15
.mu.M (hCB.sub.2) or 30 .mu.M (hCB.sub.1) GDP final). The plates
are vortexed and incubated for 60 minutes at room temperature,
filtered on Unifilters GF/B (presoaked in water) with the Tomtec or
Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM
MgCl.sub.2, 50 mM NaCl, pH 7.0). The filters are dried for 1 hour
at 55.degree. C. The radioactivity (cpm) is counted in a TopCount
(Packard) after adding 65 .mu.l/well of MS-20 scintillation liquid.
Antagonist reversal studies are done in the same way except that
(a) an agonist dose-response curve is done in the presence of a
constant concentration of antagonist, or (b) an antagonist
dose-response curve is done in the presence of a constant
concentration of agonist.
[0163] Based on the above assays, the dissociation constant (Ki)
for a particular compound of the invention towards a particular
receptor is determined using the following equation:
Ki=IC.sub.50/(1+[rad]/Kd),
[0164] Wherein IC.sub.50 is the concentration of the compound of
the invention at which 50% displacement has been observed;
[0165] [rad] is a standard or reference radioactive ligand
concentration at that moment; and
[0166] Kd is the dissociation constant of the radioactive ligand
towards the particular receptor.
[0167] Using above-mentioned assays, the Ki towards human CB.sub.1
receptors for most compounds of the invention is measured to be in
the range of 36-5700 nM. The Ki towards human CB.sub.2 receptors
for most compounds of the invention is measured to be in the range
of about 1.6-36 nM.
[0168] Using the above described assays, the IC.sub.50 towards
CB.sub.1 receptor for most of the compounds of the present
invention is generally in the range of 14.1 nM-3920.3 nM.
EXAMPLES
[0169] The invention will further be described in more detail by
the following Examples which describe methods whereby compounds of
the present invention may be prepared, purified, analyzed and
biologically tested, and which are not to be construed as limiting
the invention.
Example 1
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N-methylthiophe-
ne-2-carboxamide
##STR00010##
[0170] Step A.
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N-methylthioph-
ene-2-carboxamide
##STR00011##
[0172]
2-tert-Butyl-1-(cyclohexylmethyl)-N-methyl-1H-benzimidazol-5-amine
(30 mg, 0.100 mmol) (for preparation, see the following steps B to
F) and a catalytic amount of DMAP were dissolved in 3 mL of
dichloromethane. 2-Thiophenecarbonyl chloride (0.013 mL, 0.120
mmol) was added and the solution was stirred at RT overnight. The
solution was concentrated and the product was purified by
reversed-phase HPLC using 20-80% CH.sub.3CN/H.sub.2O and then
lyophilized to afford the desired title compound as the
corresponding TFA salt. Yield: 35 mg (67%); .sup.1H NMR (400 MHz,
METHANOL-D.sub.4) .delta. 1.22 (m, 5H), 1.61 (m, 1H), 1.63 (m,
J=1.17 Hz, 1H), 1.65 (s, 9H), 1.68 (m, 1H), 1.75 (m, 2H), 2.10 (m,
1H), 3.48 (s, 3H), 4.46 (d, J=7.62 Hz, 2H), 6.79 (dd, J=4.98, 3.81
Hz, 1H), 6.85 (dd, J=3.91, 1.17 Hz, 1H), 7.45 (dd, J=5.08, 1.17 Hz,
1H), 7.53 (dd, J=8.88, 2.05 Hz, 1H), 7.68 (d, J=1.95 Hz, 1H), 7.95
(d, J=8.79 Hz, 1H); MS (ESI) (M+H).sup.+: 410.2.
Step B. Methyl (4-fluoro-3-nitrophenyl)carbamate
##STR00012##
[0174] Methyl chloroformate (13.2 mL, 170.2 mmol) was added
dropwise to a cold (0.degree. C.) dichloromethane (200 mL) solution
of 4-fluoro-3-nitro aniline (24.15 g, 154.7 mmol) and DIPEA (35 mL,
201 mmol). The reaction mixture was stirred at rt overnight. The
solution was then diluted with 200 mL of dichloromethane and washed
with 2M HCl, brine and dried over anhydrous MgSO.sub.4. The solvent
was concentrated and the product directly used in the next step
without further purification. Yield: 35.5 g (99%); .sup.1H NMR (400
MHz, CHLOROFORM-D) .delta. 3.81 (s, 3H), 7.02 (s, 1H), 7.23 (m,
1H), 7.72 (d, J=8.59 Hz, 1H), 8.17 (dd, J=6.35, 2.64 Hz, 1H).
Step C.
Methyl{4-[(cyclohexylmethyl)amino]-3-nitrophenyl}carbamate
##STR00013##
[0176] Methyl (4-fluoro-3-nitrophenyl)carbamate (1.00 g, 4.67 mmol)
and cyclohexylmethyl amine (0.730 mL, 5.60 mmol) were stirred in
EtOH (20 mL) containing TEA (1.0 mL, 7.00 mmol) at 75.degree. C.
for 24 h. The solvent was concentrated. The residue was dissolved
in EtOAc and washed with 5% KHSO.sub.4 aqueous solution, saturated
NaHCO.sub.3 aqueous solution, brine and dried over anhydrous
MgSO.sub.4. The crude product was purified by flash chromatography
using 4:1/hexanes:EtOAc on silica gel. Yield: 1.05 g (73%); .sup.1H
NMR (400 MHz, CHLOROFORM-D) .delta. 1.04 (m, 2H), 1.25 (m, 3H),
1.69 (m, 2H), 1.77 (m, 2H), 1.83 (m, 1H), 1.86 (m, 1H), 3.14 (m,
2H), 3.78 (s, 3H), 6.46 (m, 1H), 6.84 (d, J=9.37, 1H), 7.63 (m,
1H), 8.05 (d, J=2.54 Hz, 1H), 8.09 (m, 1H).
Step D.
Methyl{3-amino-4-[(cyclohexylmethyl)amino]phenyl}carbamate
##STR00014##
[0178] Methyl{4-[(cyclohexylmethyl)amino]-3-nitrophenyl}carbamate
(1.05 g, 3.42 mmol) was dissolved in 30 mL of EtOAc containing a
catalytic amount of 10% Pd/C. The solution was shaken in a Parr
hydrogenation apparatus under H.sub.2 atmosphere (40 psi) at RT
overnight. The solution was filtered through Celite and the solvent
was evaporated. The product was directly used in the next step
without further purification. Yield: 950 mg (99%). MS (ESI)
(M+H).sup.+: 277.9.
Step E.
Methyl[2-tert-butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]carb-
amate
##STR00015##
[0180] Methyl{3-amino-4-[(cyclohexylmethyl)amino]phenyl}carbamate
(950 mg, 3.43 mmol) and DMAP (100 mg, 0.858 mmol) were dissolved in
25 mL of dichloromethane. Trimethylacetyl chloride (0.460 mL, 3.77
mmol) was added dropwise and the solution stirred at RT for 1 h.
The solvent was concentrated. The residue was divided in two and
each of them dissolved in 3 mL of glacial AcOH in a sealed tube.
The solutions were heated at 150.degree. C. using a Personal
Chemistry Smith Synthesizer microwave instrument for three
intervals of 30 min (3.times.30 min). The two tubes were combined
and the solvent was evaporated. The residue was dissolved in EtOAc
and washed with saturated NaHCO.sub.3 aqueous solution, brine and
dried over anhydrous MgSO.sub.4. The crude product was purified by
flash chromatography using 3:1/dichloromethane:diethyl ether on
silica gel. Yield: 656 mg (56%); .sup.1H NMR (400 MHz,
CHLOROFORM-D) .delta. 1.09 (m, 2H), 1.16 (m, 4H), 1.54 (s, 9H),
1.65 (m, 1H), 1.62 (m, 1H), 1.70 (m, J=1.56 Hz, 2H), 1.73 (dd,
J=5.96, 3.22 Hz, 2H), 2.02 (m, 1H), 3.78 (s, 3H), 4.10 (d, J=7.42
Hz, 2H), 6.64 (m, 1H), 7.25 (d, J=8.79 Hz, 1H), 7.39 (m, 1H), 7.59
(d, J=1.76 Hz, 1H).
Step F.
2-tert-Butyl-1-(cyclohexylmethyl)-N-methyl-1H-benzimidazol-5-amine
##STR00016##
[0182]
Methyl[2-tert-butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]carba-
mate (650 mg, 1.89 mmol) was dissolved in 20 mL of THF at 0.degree.
C. under nitrogen. 1M HCl/ether (2.65 mL, 2.65 mmol) was added
dropwise and the solution stirred at 0.degree. C. for 15 min.
LiAlH.sub.4 (360 mg, 9.45 mmol) was then slowly added and the
solution stirred at RT overnight. The reaction mixture was quenched
at 0.degree. C. by addition of MeOH (5 mL) followed by water (10
mL). The solution was diluted with EtOAc and washed with saturated
NaHCO.sub.3 aqueous solution, brine and dried over anhydrous
MgSO.sub.4. The solvent was evaporated and the product was used
directly in the next step without further purification. Yield: 544
mg (96%). .sup.1H NMR (400 MHz, CHLOROFORM-D) .delta. 1.08 (m, 2H),
1.17 (m, 3H), 1.53 (s, 9H), 1.64 (s, 2H), 1.67 (s, 2H), 1.72 (m,
2H), 2.02 (m, 1H), 2.86 (s, 3H), 4.06 (d, J=7.42 Hz, 2H), 6.60 (dd,
J=8.69, 2.25 Hz, 1H), 6.99 (d, J=2.15 Hz, 1H), 7.12 (d, J=8.59 Hz,
1H).
Example 2
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N,2,2-trimethyl-
propanamide
##STR00017##
[0184] Following the same procedure used in Example 1, Step A,
using
2-tert-butyl-1-(cyclohexylmethyl)-N-methyl-1H-benzimidazol-5-amine
(40 mg, 0.134 mmol) and trimethylacetyl chloride (0.021 mL, 0.174
mmol) in 3 mL of dichloromethane. The product was purified by
reversed-phase HPLC using 20-80% CH.sub.3CN/H.sub.2O on a C-18
column and then lyophilized to afford the desired title compound as
the corresponding TFA salt. Yield: 60 mg (90%); .sup.1H NMR (400
MHz, METHANOL-D.sub.4) .delta. 1.07 (s, 9H), 1.23 (m, 5H), 1.63 (m,
2H), 1.66 (s, 10H), 1.76 (m, 2H), 2.11 (m, 1H), 3.28 (s, 3H), 4.47
(d, J=7.62 Hz, 2H), 7.51 (dd, J=8.79, 1.95 Hz, 1H), 7.65 (d, J=1.37
Hz, 1H), 7.96 (d, J=8.98 Hz, 1H); MS (ESI) (M+H).sup.+: 384.3;
Anal. Calcd for C.sub.24H.sub.37N.sub.3O+1.7 TFA+0.6H.sub.2O: C,
55.95; H, 6.84; N, 7.14. Found: C, 55.92; H, 6.81; N, 7.07.
Example 3
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N,2-dimethylpro-
panamide
##STR00018##
[0186] Following the same procedure used in Example 1, Step A,
using
2-tert-butyl-1-(cyclohexylmethyl)-N-methyl-1H-benzimidazol-5-amine
(40 mg, 0.134 mmol) and isobutyryl chloride (0.018 mL, 0.174 mmol)
in 3 mL of dichloromethane. The product was purified by
reversed-phase HPLC using 20-80% CH.sub.3CN/H.sub.2O on a C-18
column and then lyophilized to afford the desired title compound as
the corresponding TFA salt. Yield: 58 mg (90%); .sup.1H NMR (400
MHz, METHANOL-D.sub.4) .delta. 0.99 (s, 6H), 1.24 (m, 5H), 1.65 (m,
2H), 1.66 (s, 10H), 1.76 (s, 2H), 2.11 (m, 1H), 2.46 (m, 1H), 3.27
(s, 3H), 4.47 (d, J=7.62 Hz, 2H), 7.52 (d, J=8.59 Hz, 1H), 7.67 (s,
1H), 7.99 (d, J=8.79 Hz, 1H); MS (ESI) (M+H).sup.+: 370.2; Anal.
Calcd for C.sub.23H.sub.35N.sub.3O+1.7 TFA+0.3H.sub.2O: C, 55.75;
H, 6.61; N, 7.39. Found: C, 55.77; H, 6.52; N, 7.45.
Example 4
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N,3-dimethylbut-
anamide
##STR00019##
[0188] Following the same procedure used in Example 1, Step A,
using
2-tert-butyl-1-(cyclohexylmethyl)-N-methyl-1H-benzimidazol-5-amine
(30 mg, 0.100 mmol) and isovaleryl chloride (0.016 mL, 0.130 mmol)
in 3 mL of dichloromethane. The product was purified by
reversed-phase HPLC using 20-80% CH.sub.3CN/H.sub.2O on a C-18
column and then lyophilized to afford the desired title compound as
the corresponding TFA salt. Yield: 40 mg (80%); .sup.1H NMR (400
MHz, METHANOL-D.sub.4) .delta. 0.79 (brs, 6H), 1.22 (brs, 6H), 1.63
(s, 13H), 1.75 (brs, 1H), 1.97 (m, 1H), 2.03 (m, 1H), 2.10 (m, 1H),
3.27 (s, 3H), 4.41 (d, J=7.42 Hz, 2H), 7.40 (dd, J=1.66, 8.88 Hz,
1H), 7.58 (s, 1H), 7.88 (d, J=8.79 Hz, 1H); MS (ESI) (M+H).sup.+:
384.3; Anal. Calcd for C.sub.24H.sub.37N.sub.3O+1.0
TFA+0.3H.sub.2O: C, 62.08; H, 7.73; N, 8.35. Found: C, 62.18; H,
7.57; N, 8.36.
Example 5
N-[2-tert-Butyl-1-(cyclohexylmethyl)-H-benzimidazol-5-yl]-N'-isopropyl-N-m-
ethylurea
##STR00020##
[0190] Following the same procedure used in Example 1, Step A,
using
2-tert-butyl-1-(cyclohexylmethyl)-N-methyl-1H-benzimidazol-5-amine
(40 mg, 0.134 mmol) and isopropyl isocyanate (0.015 mL, 0.161 mmol)
in 5 mL of dichloromethane. The product was purified by
reversed-phase HPLC using 20-80% CH.sub.3CN/H.sub.2O on a C-18
column and then lyophilized to afford the desired title compound as
the corresponding TFA salt. Yield: 54 mg (81%); .sup.1H NMR (400
MHz, METHANOL-D.sub.4) .delta. 1.10 (d, J=6.44 Hz, 6H), 1.22 (m,
5H), 1.63 (m, 2H), 1.66 (s, 9H), 1.67 (m, 1H), 1.75 (m, 2H), 2.11
(m, 1H), 3.28 (s, 3H), 3.90 (q, J=6.59 Hz, 1H), 4.45 (d, J=7.62 Hz,
2H), 7.47 (dd, J=8.98, 1.95 Hz, 1H), 7.60 (d, J=1.56 Hz, 1H), 7.89
(d, J=8.98 Hz, 1H); MS (ESI) (M+H).sup.+: 385.2; Anal. Calcd for
C.sub.23H.sub.36N.sub.4O+1.5 TFA+0.4 H.sub.2O: C, 55.49; H, 6.86;
N, 9.95. Found: C, 55.42; H, 6.83; N, 9.98.
Example 6
N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-yl]acetam-
ide
##STR00021##
[0191] Step A.
N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-yl]aceta-
mide
##STR00022##
[0193] DMAP (0.65 g, 5.3 mmol) was added to a suspension of
N-{3-amino-4-[(cyclohexylmethyl)amino]phenyl}acetamide (2.09 g, 8.0
mmol) (for preparation, see the following steps B, C and D) in
dichloromethane (40 mL) at -10.degree. C., followed by addition of
2,2-dimethylbutyryl chloride (1.51 g, 11.2 mmol). The resulting
mixture was stirred overnight at room temperature. After
evaporation of the solvent, 4.14 g of a brown solid was obtained,
which was consistent with the desired coupling product. MS (ESI)
(M+H).sup.+=360.07.
[0194] 308 mg of the above crude product was dissolved in
1,2-dichloroethane (5 mL) in a Teflon-capped test tube. The vessel
was irradiated by microwave for 3 h at 170.degree. C. The mixture
was diluted with EtOAc (100 mL), washed with 2N NaOH aqueous
solution (10 mL), saturated NaCl aqueous solution (10 mL) and dried
over Na.sub.2SO.sub.4. After filtration and evaporation, the
residue was purified by MPLC (EtOAc as eluent on silica gel) to
give the desired title compound as a light yellow solid (111.0 mg,
55%). .sup.1HNMR (400 MHz, CD.sub.3OD): .delta. 0.84 (t, J=7.52 Hz,
3H), 1.25 (m, 5H), 1.63 (m, 2H), 1.66 (s, 6H), 1.70 (m, 1H), 1.77
(m, 2H), 2.01 (q, J=7.42 Hz, 2H), 2.10 (m, 1H), 2.18 (s, 3H), 4.44
(d, J=7.81 Hz, 2H), 7.50 (dd, J=8.98, 1.95 Hz, 1H), 7.84 (d, J=9.18
Hz, 1H), 8.44 (d, J=1.76 Hz, 1H). MS (ESI) (M+H).sup.+: 342.05.
Anal. Calcd for C.sub.21H.sub.31N.sub.3O+1.10 TFA+0.40H.sub.2O
(474.13): C, 58.77; H, 6.99; N, 8.66. Found: C, 58.86; H, 6.90; N,
8.91.
Step B. N-(4-fluoro-3-nitrophenyl)acetamide
##STR00023##
[0196] 4-Fluoro-3-nitro-aniline (45.0 g, 288.2 mmol) was added
portionwise to acetic anhydride (150 mL) at room temperature. The
reaction mixture was stirred at room temperature for 2 h. The white
solid was collected and dried in vacuo to give the desired title
compound (42.0 g, 70%). .sup.1HNMR (400 MHz, CDCl.sub.3): .delta.
2.23 (s, 3H), 7.26 (m, 1H), 7.50 (s broad, 1H), 7.87 (m, 1H), 8.23
(dd, J=6.44, 2.73 Hz, 1H).
Step C. N-{4-[(cyclohexylmethyl)amino]-3-nitrophenyl}acetamide
##STR00024##
[0198] Cyclohexylmethylamine (2.86 mL, 2.49 g, 22.0 mmol) was added
to a mixture of N-(4-fluoro-3-nitrophenyl)acetamide (3.96 g, 20.0
mmol) and sodium carbonate (4.66 g, 44 mmol) in EtOH (50 mL) at
room temperature. The reaction mixture was heated for 48 h at
60.degree. C., and diluted with H.sub.2O (800 mL). The orange solid
was precipitated out and collected to give the desired title
product (6.60 g, 100%). MS (ESI) (M+H).sup.+: 292.32.
Step D. N-{3-amino-4-[(cyclohexylmethyl)amino]phenyl}acetamide
##STR00025##
[0200] The above crude product
(N-{4-[(cyclohexylmethyl)amino]-3-nitrophenyl}acetamide) was
hydrogenated in ethyl acetate (300 mL) catalyzed by 10% Pd/C (0.5
g) at 20-30 psi H.sub.2 in Parr shaker for 4.5 h at room
temperature. After filtration through celite and concentration,
5.08 g (97%) of a purple solid was obtained. which was used in the
next step without further purification. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 1.00 (m, 2H), 1.24 (m, 3H), 1.59 (m, 2H), 1.72
(m, 2H), 1.84 (m, 2H), 2.13 (s, 3H), 2.91 (d, J=6.64 Hz, 2H), 3.37
(s broad, 3H), 6.56 (d, J=8.40 Hz, 1H), 6.69 (dd, J=8.30, 2.25 Hz,
1H), 6.98 (s, 1H), 7.12 (d, J=2.34 Hz, 1H). MS (ESI) (M+H).sup.+:
262.31.
Example 7
N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-yl]-N'-is-
opropylurea
##STR00026##
[0201] Step A.
N-[1-(cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-yl]-N'-i-
sopropylurea
##STR00027##
[0203] A mixture of
1-(cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-amine
hydrochloride (48.5 mg, 0.127 mmol), diisopropylethylamine (148 mg,
200 uL, 1.15 mmol) and isopropylisocynate (0.5 mL) in
1,2-dichloroethane (5 mL) was heated for 2 h at 60.degree. C. Upon
evaporation of the solvent, the residue was treated with 2N NaOH
aqueous solution (5 mL), extracted with EtOAc (3.times.20 mL). The
combined organic phases were washed with saturated NaCl aqueous
solution (10 mL) and dried over Na.sub.2SO.sub.4. After filtration
and evaporation, the residue was purified by MPLC (EtOAc as eluent
on silica gel) to give the desired title compound as a syrup (34.8
mg, 71%). .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 0.84 (t,
J=7.52 Hz, 3H), 1.20 (d, J=6.44 Hz, 6H), 1.25 (m, 5H), 1.63 (m,
2H), 1.66 (s, 6H), 1.70 (m, 1H), 1.78 (m, 2H), 2.00 (q, J=7.42 Hz,
2H), 2.10 (m, 1H), 3.91 (m, 1H), 4.42 (d, J=7.62 Hz, 2H), 7.28 (m,
1H), 7.76 (d, J=9.18 Hz, 1H), 8.18 (d, J=1.56 Hz, 1H). MS (ESI)
(M+H).sup.+: 385.2. Anal. Calcd for C.sub.23H.sub.36N.sub.4O+1.20
TFA+0.80H.sub.2O (535.81): C, 56.94; H, 7.30; N, 10.46. Found: C,
56.90; H, 7.27; N, 10.27.
Step B.
1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-amin-
e
##STR00028##
[0205]
N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-yl-
]acetamide (105.4 mg, 0.309 mmol) was dissolved in ethanol (3 mL)
and 2NHCl aqueous solution (2 mL) in a Teflon-capped test tube. The
vessel was irradiated by microwave for 45 min. at 120.degree. C.
After evaporation and drying in vacuo, 117.8 mg (100%) of the title
compound was obtained as a grey white solid. .sup.1H NMR (400 MHz,
CD.sub.3CD): .delta. 0.87 (t, J=7.52 Hz, 3H), 1.27 (m, 5H), 1.66
(m, 3H), 1.71 (s, 6H), 1.78 (m, 2H), 2.05 (q, J=7.42 Hz, 2H), 2.13
(m, 1H), 4.53 (d, J=7.62 Hz, 2H), 7.66 (dd, J=8.79, 1.56 Hz, 1H),
7.97 (d, J=1.76 Hz, 1H), 8.17 (d, J=8.79 Hz, 1H). MS (ESI)
(M+H).sup.+: 300.05.
Example 8
N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-yl]-2,2-d-
imethylbutanamide
##STR00029##
[0207] 2,2-Dimethylbutyryl chloride (24.6 mg, 0.18 mmol) was added
to a mixture of
1-(cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1H-benzimidazol-5-amine
hydrochloride (65.0 mg, 0.15 mmol) (for preparation see in Example
7, step B) and DMAP (73.3 mg, 0.60 mmol) in acetonitrile (5 mL) at
0.degree. C. The mixture was stirred for 6 h at room temperature,
diluted with EtOAc (50 mL), washed with saturated NaHCO.sub.3
aqueous solution (10 mL), saturated NaCl aqueous solution (10 mL)
and dried over Na.sub.2SO.sub.4. After filtration and evaporation,
the residue was purified by MPLC (EtOAc as eluent on silica gel) to
give the desired title compound as a syrup (51.6 mg, 87%). .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 0.84 (t, J=7.52 Hz, 3H), 0.91
(t, J=7.52 Hz, 3H), 1.25 (m, 5H), 1.28 (s, 6H), 1.64 (m, 3H), 1.67
(s, 6H), 1.72 (q, J=7.49 Hz, 2H), 1.78 (m, 2H), 2.02 (q, J=7.49 Hz,
2H), 2.13 (m, 1H), 4.45 (d, J=7.62 Hz, 2H), 7.64 (dd, J=8.98, 1.76
Hz, 1H), 7.85 (d, J=9.18 Hz, 1H), 8.34 (s, 1H). MS (ESI)
(M+H).sup.+: 398.3. Anal. Calcd for C.sub.25H.sub.39N.sub.3O+1.50
TFA+0.70H.sub.2O (581.25): C, 57.86; H, 7.27; N, 7.23. Found: C,
57.90; H, 7.19; N, 7.34.
Example 9
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]acetamide
##STR00030##
[0209] Following the same procedure of Example 6, a mixture of
N-{3-amino-4-[(cyclohexylmethyl)amino]phenyl}acetamide (1.57 g, 6.0
mmol) (for preparation see in Example 6, step D) and DMAP (0.15 g,
1.2 mmol) in dichloromethane (70 mL) was treated with
trimethylacetyl chloride (0.83 g, 6.6 mmol) at -10.degree. C. After
evaporation of the solvent, the residue was dissolved in
1,2-dichloroethane (40 mL) and then divided into eight
Teflon-capped test tubes. The vessels were irradiated by microwave
for 2 h at 170.degree. C. After purification by MPLC (EtOAc as
eluent on silica gel), the desired title compound was obtained as a
white solid (1.42 g, 72%). .sup.1HNMR (400 MHz, CD.sub.3OD):
.delta. 1.24 (m, 5H), 1.64 (m, 2H), 1.67 (s, 9H), 1.70 (m, 1H),
1.77 (m, 2H), 2.12 (m, 1H), 2.18 (s, 3H), 4.45 (d, J=7.62 Hz, 2H),
7.50 (m, 1H), 7.84 (d, J=8.98 Hz, 1H), 8.43 (d, J=1.95 Hz, 1H). MS
(ESI) (M+H).sup.+: 328.3. Anal. Calcd for
C.sub.20H.sub.29N.sub.3O+1.20 TFA+0.30H.sub.2O (469.71): C, 57.28;
H, 6.61; N, 8.95. Found: C, 57.34; H, 6.67; N, 8.85.
Example 10
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-N-methylacetami-
de
##STR00031##
[0211] Sodium hydride (201.5 mg, 5.04 mmol) was added to a solution
of
N-[2-tert-butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]acetamide
(549.8 mg, 1.68 mmol) (for preparation see in Example 9) in THF (50
mL) at 0.degree. C. Stirring for 30 min., iodomethane was added.
The resulting mixture was stirred overnight at room temperature and
quenched with saturated NaHCO.sub.3 aqueous solution (5 mL) and
water (10 mL). Two phases were separated. The aqueous was extracted
with EtOAc (3.times.20 mL). The combined organic phases were washed
with saturated NaHCO.sub.3 aqueous solution (20 mL), saturated NaCl
aqueous solution (20 mL) and dried over Na.sub.2SO.sub.4. After
evaporation of the solvent, the residue was purified by MPLC (EtOAc
as eluent on silica gel) to give the desired title compound as a
white solid (580.5 mg, 100%). .sup.1HNMR (400 MHz, CD.sub.3OD):
.delta. 1.26 (m, 5H), 1.67 (m, 2H), 1.69 (s, 9H), 1.71 (m, 1H),
1.78 (m, 2H), 1.87 (s, 3H), 2.14 (m, 1H), 3.30 (s, 3H), 4.49 (d,
J=7.62 Hz, 2H), 7.55 (d, J=8.40 Hz, 1H), 7.71 (s, 1H), 8.00 (d,
J=8.40 Hz, 1H). MS (ESI) (M+H).sup.+: 342.3. Anal. Calcd for
C.sub.21H.sub.31N.sub.3O+1.30 TFA+0.80H.sub.2O (504.14): C, 56.23;
H, 6.78; N, 8.33. Found: C, 56.21; H, 6.77; N, 8.17.
Example 11
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-2,2-dimethylpro-
panamide
##STR00032##
[0212] Step A:
N-[2-tert-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-2,2-dimethylpr-
opanamide
##STR00033##
[0214]
N-{3-Amino-4-[(cyclohexylmethyl)amino]phenyl}-2,2-dimethylpropanami-
de (for preparation, see following Steps B to D) (174 mg, 0.573
mmol) and DMAP (18 mg, 0.143 mmol) were dissolved in 5 mL of DCM.
Trimethylacetyl chloride (0.077 mL, 0.630 mmol) was added dropwise
and the solution was stirred at RT for 1 h. The solvent was
evaporated. The residue was dissolved in 3 mL of glacial acetic
acid in a sealed tube and the solution was heated at 150.degree. C.
in a Smithsynthesizer (Personal Chemistry) microwave instrument for
1 h. The solvent was evaporated in vacuo. The residue was dissolved
in EtOAc and washed with saturated NaHCO.sub.3 solution, brine and
dried over anhydrous MgSO.sub.4. The product was purified by
reversed-phase HPLC using 20-80% CH.sub.3CN/H.sub.2O on a C-18
column and then lyophilized affording the desired title compound as
the corresponding TFA salt. Yield: 170 mg (61%). .sup.1HNMR (400
MHz, METHANOL-D.sub.4): .delta. 1.21 (m, 5H), 1.29 (s, 9H), 1.61
(m, 2H), 1.64 (s, 9H), 1.66 (m, 1H), 1.75 (m, 2H), 2.09 (m, 1H),
4.42 (d, J=7.62 Hz, 2H), 7.62 (dd, J=9.18, 1.95 Hz, 1H), 7.81 (d,
J=9.18 Hz, 1H), 8.31 (d, J=1.56 Hz, 1H); MS (ESI) (M+H).sup.+
370.2; Anal. Calcd for C.sub.23H.sub.35N.sub.3O+1.6
TFA+0.2H.sub.2O: C, 56.64; H, 6.71; N, 7.56. Found: C, 56.67; H,
6.74; N, 7.53.
Step B: N-(4-Fluoro-3-nitrophenyl)-2,2-dimethylpropanamide
##STR00034##
[0216] 4-Fluoro-3-nitroaniline (500 mg, 3.20 mmol) and DMAP (586
mg, 4.80 mmol) were dissolved in 25 mL of DCM. Trimethylacetyl
chloride (0.587 mL, 4.80 mmol) was added dropwise and the solution
was stirred at rt for 3 h. The solution was washed with 5%
KHSO.sub.4 solution, saturated NaHCO.sub.3 solution, brine and
dried over anhydrous MgSO.sub.4. The crude product was purified by
flash chromatography using 35% EtOAc in hexanes as eluent on silica
gel to produce the desired title compound. Yield: 713 mg (93%).
.sup.1H NMR (400 MHz, CHLOROFORM-D:) .delta. 1.34 (s, 9H), 7.25
(dd, J=10.25, 9.08 Hz, 1H), 7.50 (br.s, 1H), 7.88 (ddd, J=9.08,
3.71, 2.83 Hz, 1H), 8.26 (dd, J=6.44, 2.73 Hz, 1H).
Step C:
N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl}-2,2-dimethylpropanam-
ide
##STR00035##
[0218] N-(4-Fluoro-3-nitrophenyl)-2,2-dimethylpropanamide (158 mg,
0.658 mmol) and cyclohexylmethylamine (0.100 mL, 0.790 mmol) were
stirred in 3 mL of EtOH containing triethylamine (0.140 mL, 0.987
mmol) at 75.degree. C. for 24 h. The solvent was evaporated. The
residue was dissolved in EtOAc and washed with 5% KHSO.sub.4
solution, saturated NaHCO.sub.3 solution, brine and dried over
anhydrous MgSO.sub.4--Yield: 217 mg (99%). .sup.1H NMR (400 MHz,
CHLOROFORM-D): .delta. 0.98-1.09 (m, 2H), 1.17-1.28 (m, 3H), 1.31
(s, 9H), 1.65-1.73 (m, 2H), 1.74-1.80 (m, 2H), 1.82-1.84 (m, 1H),
1.85-1.88 (m, 1H), 3.15 (dd, J=6.64, 5.47 Hz, 2H), 6.83 (d, J=9.37
Hz, 1H), 7.23 (br.s, 1H), 7.82 (dd, J=9.18, 2.54 Hz, 1H), 8.10 (d,
J=2.54 Hz, 1H), 8.11-8.13 (m, 1H).
Step D:
N-{3-Amino-4-[(cyclohexylmethyl)amino]phenyl}-2,2-dimethylpropanam-
ide
##STR00036##
[0220]
N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl}-2,2-dimethylpropanami-
de (215 mg, 0.645 mmol) was dissolved in 20 mL of EtOAc containing
a catalytic amount of 10% Pd/C. The solution was shaken in a Parr
hydrogenation apparatus under H.sub.2 atmosphere (45 psi) at RT for
24 h. The solution was filtered through Celite and the solvent
evaporated to give the desired product. Yield: 175 mg (89%); MS
(ESI) (M+H).sup.+ 304.04.
* * * * *